Organization | RTI Health Solutions

RTI Health Solutions Report issue

For profit Phase 3

Founded: Durham NC United States (2001)

Organization Overview

First Clinical Trial

2001

NCT01434173

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2017

Timeline

NOW

Now

Alternative names

RTI health solutions, US

Active Ingredients

Drugs in Phase 3 Trials (1)

asimadoline (3 trials)

Drugs in Other Trials (12)

cefuroxime (zinacef) (1 trial)

clarithromycin (biaxin) (1 trial)

clavulanate (Augmentin) (1 trial)

cyproviron (1 trial)

doxycycline (vibramycin) (1 trial)

ethinyl estradiol (Estinyl) (1 trial)

indacaterol (arcapta neohaler) (1 trial)

levofloxacin (levaquin) (1 trial)

moxifloxacin (avelox) (1 trial)

olodaterol (striverdi respimat) (1 trial)

procaine benzylpenicillin (novocaine) (1 trial)

telithromycin (ketek) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Diarrhea (Phase 3)

Ileus (Phase 2)

Irritable Bowel Syndrome (Phase 3)

Syndrome (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 6
# of Trial APIs: 13